<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01722513</url>
  </required_header>
  <id_info>
    <org_study_id>NCT20120312</org_study_id>
    <nct_id>NCT01722513</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy</brief_title>
  <official_title>Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomized, controlled study is to investigate the effect of
      pretreatment with intravenous Alprostadil on the incidence of CIN in a high-risk population
      of patients with both type 2 diabetes mellitus (T2DM) and CKD undergoing coronary
      angiography, and evaluate the influence of such potential benefit on short-term outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of cardiac angiography and percutaneous coronary interventions (PCI) has increased
      steadily in recent years. This has resulted in the increasing incidence of contrast-induced
      nephropathy (CIN). Major risk factors for CIN include older age, diabetes mellitus (DM),
      chronic kidney disease (CKD).

      The aim of this prospective, randomized, controlled study is to investigate the effect of
      pretreatment with intravenous Alprostadil on the incidence of CIN in a high-risk population
      of patients with both type 2 diabetes mellitus (T2DM) and CKD undergoing coronary
      angiography, and evaluate the influence of such potential benefit on short-term outcome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>72 h</time_frame>
    <description>An absolute increase in SCr &gt;=0.5mg/dL（&gt;=44.2μmmol/L）or a &gt;= 25% increase in SCr from baseline to 72h after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>30 d</time_frame>
    <description>The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Alprostadil, Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil ﹠control</intervention_name>
    <description>control:Normal salin 1cc/kg/hr before and after angiography</description>
    <arm_group_label>Alprostadil, Control</arm_group_label>
    <other_name>Drug: Alprostadil</other_name>
    <other_name>lipo-alprostadil</other_name>
    <other_name>Prostaglandin E1</other_name>
    <other_name>Drug: normal salin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient that underwent coronary angiography

          -  T2DM

          -  CKD stages 2 and 3, eGFR 30 to 89ml/min per 1.73m2

          -  Alprostadil naive, or not on Alprostadil treatment for at least 14 days

          -  Withdrawal metformin or aminophylline for 48h before angiography

        Exclusion Criteria:

          -  serum Cr. More than 3 mg/dl

          -  electrolyte and acid-base imbalance

          -  pulmonary edema

          -  allergy to Alprostadil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ya-Wei Xu, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.shdsyy.com.cn</url>
    <description>Shanghai Tenth People's Hospital</description>
  </link>
  <link>
    <url>http://www.sda.gov.cn/WS01/CL0001/</url>
    <description>State Food and Drug Administration ,China</description>
  </link>
  <results_reference>
    <citation>Koch JA, Plum J, Grabensee B, Mödder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000 Jan;15(1):43-9.</citation>
    <PMID>10607766</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2012</study_first_submitted>
  <study_first_submitted_qc>November 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2012</study_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ya-Wei Xu</investigator_full_name>
    <investigator_title>MD FACC</investigator_title>
  </responsible_party>
  <keyword>Contrast Induced Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

